Mainstream

ADC Therapeutics targets $600M–$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts

ADC Therapeutics targets $600M–$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts

Post ContentadctRead More

You might also be interested in reading XRP Rebounds From $1.27 Low but Market Fear Still Looms Over Recovery.

August 12, 2025
In Mainstream